T-cell receptor
AssigneeUniversity College Cardiff Consultants Limited
InventorsAndrew Sewell, Garry Dolton
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or bispecific to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition or bispecific comprising said TCR.
Claims30
A vector encoding a T-cell receptor (TCR) that comprises
- a. an α chain that comprises CDR1α, CDR2α, and CDR3α amino acid sequences that are at least 88% identical to the amino acid sequences of SEQ ID Nos:
- 3, 4, and 1, respectively;
- and
- b. a β chain that comprises CDR1β, CDR2β, and CDR3β amino acid sequences that are at least 88% identical to the amino acid sequences of SEQ ID Nos:
- 5, 6, and 2, respectively.
Dependencies are inferred from the claim text.